

Funding guidelines for mpox response

Version 2.0



DOCUMENT ADMINISTRATION

Version Number	APPROVAL PROCESS	DATE
1.0	Prepared by: Mpox Delivery Funding Working group (FD&R, GHS, C19 Delivery Team)	August / September 2024
	Reviewed & Approved by: Mpox Leadership Team	Effective from: 12 September 2024
2.0	Prepared by: Mpox Delivery Funding Working group (FD&R, GHS, C19 Delivery Team)	October / November 2024
	Reviewed by: Mpox Leadership Team	12 November 2024
	Approved by: Chief Executive Officer	XXX

Contents

Background and mpox description	3
Target audience	3
Guiding Principles	3
Gavi support	
Accessing Vaccines	4
Accessing Delivery funding	5
Eligible expenditures	6
Process for applying to Gavi	8
FAQs	10
Annex 1 – Countries eligible for reprogramming of Gavi CDS grants	11

Background and mpox description

Africa Centre for Disease Control (CDC) declared mpox as a Public Health Emergency of Continental Security (PHECS) in Africa on 13 August 2024¹ and the World Health Organisation (WHO) declared a public health emergency of international concern (PHEIC) for mpox in 14 August 2024². Gavi also extended certain flexibilities for this emergency per its Fragilities, Emergencies and Displaced Populations (FED) Policy³ on 15 August 2024.

The objective of these guidelines is to outline Gavi's support towards countries mpox outbreak response, specifically the details on the funding pathways and application processes for mpox vaccination delivery support, as well as country eligibility and eligible expenditures for mpox vaccination delivery funding programming.

Target audience

These guidelines are intended for Immunisation Programme Managers, Alliance partners, Gavi Secretariat country teams, and other stakeholders including Civil Society Organisations (CSOs) supporting the response to mpox outbreak and the delivery of mpox vaccines.

Guiding Principles

- Vaccines, funding and programming must be responsive to countries' needs and show demonstrated ability to absorb funds.
- Countries' strategies for timely, targeted and effective vaccination of priority populations should align with available normative guidance from WHO and Africa CDC.
- Funding should be complementary and not displace support from domestic resources or other donors or partners.
- Activities funded must align with Gavi guidance on eligible and ineligible expenditures
 / activities listed below.
- Programming to consider gender and equity for an effective and equitable delivery of funded doses to the populations that need it most.

¹ <u>https://africacdc.org/news-item/africa-cdc-declares-mpox-a-public-health-emergency-of-continental-security-mobilizing-resources-across-the-continent/</u>

² https://www.who.int/news/item/14-08-2024-who-director-general-declares-mpox-outbreak-a-public-health-emergency-of-international-concern

³ https://www.gavi.org/news/media-room/gavi-statement-mpox-emergency-africa

- Funding will be awarded in a rapid and responsible way, recognizing that country needs vary.
- The full range of in-country partners should be engaged in the design and implementation of this response funding, including international non-governmental organisations (iNGOs), CSOs, and other local partners based on their comparative advantages.

Gavi support

Accessing Vaccines

Gavi has secured 500,000 doses of the MVA-BN (Modified Vaccinia Ankara - Bavarian Nordic) vaccine⁴ via an Advance Purchase Agreement (APA). It is also facilitating donations of mpox vaccination doses when requested. Allocations of mpox vaccination doses, including Gavi APA doses and Gavi facilitated donated doses are approved by the principals of Africa CDC, CEPI, Gavi, UNICEF and WHO following a recommendation by the Technical Review Committee (TRC), convened by the mpox Continental Incidence Management Support Team jointly led by Africa CDC and WHO/AFRO.

There are other vaccine supply sources beyond those facilitated by Gavi, including vaccines procured via UNICEF's emergency tender, donated doses facilitated via the Africa CDC and those via bilateral donations.

⁴ As of the date of this publication.

Accessing Delivery funding

There are two pathways to Gavi mpox vaccination delivery funding support:

Reprogramming of existing C19 Delivery Support (CDS) grant

Scope

- Activities related to mpox vaccination preparedness / readiness, mpox vaccination delivery, protecting routine immunisation and protecting health care workers
- Gavi guidance on eligible & ineligible activities

Funding ceiling

Up to \$5m / 20% of CDS grant value*
 Eligibility

 Gavi eligible countries in African continent who have suspected / confirmed cases of mpox

*Unless exceptionally approved.

Note: Reprogramming of HSS is not in scope for Mpox outbreak response

Gavi mpox vaccine delivery funding

Scope

- Mpox vaccination delivery support focused on timely and effective vaccination of targeted populations
- Gavi guidance on eligible & ineligible activities
- Disbursement linked to allocation of doses

Funding ceiling

• \$7 per dose

Eligibility

- Gavi eligible countries in African continent that are allocated Gavi APA doses or Gavi facilitated donated doses
- Eligible countries who have received an mpox vaccine allocation by the TRC should program their mpox delivery support and any subsequent funding needs can be complemented by CDS reprogramming.
- Country without an mpox vaccine allocation, CDS reprogramming will be the source for mpox preparedness and delivery support.

Eligibility for reprogramming

Gavi eligible countries⁵ on the African continent who have reported a suspected or confirmed case of mpox since January 2024 are eligible for reprogramming. It may not be feasible for all eligible countries to reprogramme their C19 Delivery Support funding (CDS) towards mpox given competing priorities – and feasibility should be discussed between the countries and the Gavi Senior Country Managers.

Eligibility for new Gavi mpox vaccination delivery funding

In order to be eligible for Gavi mpox vaccination delivery funding, a country must meet these three criteria;

⁵ Limited to Gavi core eligible countries. -Gavi Middle Income Countries are not eligible for this support

- A Gavi eligible country⁵ on the African continent who has reported a suspected or confirmed case of mpox since January 2024.
- Have an mpox vaccination plan and/or national mpox preparedness & response plan (draft or approved by the cross-partner mpox Continental IMST and Technical Review Committee).
- The country has received and confirmed acceptance of an allocation of Gavi facilitated doses (APA doses or Gavi facilitated donated doses).

For the allocation of mpox vaccination delivery funding, Gavi will provide up to a ceiling of US\$7 per Gavi-facilitated dose that is allocated by the TRC (approved by Africa CDC, CEPI, UNICEF and WHO), or a lumpsum of US\$ 75,000, whichever is higher.

Eligible expenditures

This section describes the types of activities and expenditures that Gavi would and would not support in response to the current mpox outbreak. The below is informed by Gavi's experience and precedence in response to other Public Health Events, COVID-19, Gavi's First Response Fund (FRF) permitted use-cases and Gavi's existing Programme Funding Guidelines.

To note, countries who are eligible for mpox delivery funding support are eligible to subsequently reprogram CDS funding, if additional funding support is required on top of the mpox delivery funding allocation (please follow the process as described in pathway 2 below). This should be complementary to the funding programmed for mpox delivery funding and in line with the eligible activities as described below.

i. Eligible expenditures for both CDS reprogramming and Gavi mpox vaccination delivery funding pathways

Vaccines / vaccination related activities

- Financing mpox vaccination plan implementation (per country plans, focusing on target population);
- Refinement of mpox vaccination plans (aligned with WHO, SAGE, Africa CDC or other standards and guidance);
- Constitution and support for in-country (national and sub-national) coordination and operational mechanisms, and regular coordination activities;
- Targeted HMIS, LMIS, digital health and data infrastructure to accommodate mpox outbreak response, vaccination and vaccine safety data collection, monitoring, reporting, accountability and analytics;
- Vaccination demand, social mobilisation, risk communication, community and civil society engagement and advocacy related activities;
- Targeted vaccine-related surveillance expenditures;

- Support for surge workforce (inclusive of targeted incentive payments linked to mpox vaccination outbreak response, leadership and coordination support), capacity / capacitating or upskilling current workforce.
- Design, implement and monitor safeguarding policies, practices, and accountability measures to address gender-based violence as well as sexual exploitation and abuse, to ensure safety of users and providers.

Note that once a country receives funding support from Gavi, these funds may be used to support all eligible activities listed above across all sourced mpox vaccines in country (i.e.: the use of funds are not restricted to Gavi facilitated doses only).

ii. Additional Eligible Activities for CDS reprogramming only

Preparedness/Readiness related vaccine activities

While Gavi mpox vaccination delivery funding is uniquely focused on the timely and effective vaccination of target populations, reprogrammed Gavi funds can be directed towards a broader set of mpox response activities. Importantly, this includes preparedness and readiness related vaccination activities that need to take place prior to allocation of doses and vaccination beginning, such as the development of plans (aligned with WHO, SAGE, Africa CDC and other standards and guidance) and support towards initial regulatory approvals.

Non vaccine / vaccination related activities

While the majority of reprogrammed CDS funds are intended to support vaccination related activities, select investments beyond vaccination would be eligible (based on learnings from earliest COVID-19 pandemic response activities and country needs)⁶. A key example here would be the flexibility to support targeted interventions that may help limit or avert spread of the disease (e.g.: infection prevention and control measures) and / or protect frontline health workers (e.g. purchase of personal protective equipment).

Protection of routine immunisation during mpox response

Beyond these, investments linked to protecting routine immunisation are also eligible. Activities under this objective could include early vaccination of health workers, development

⁶ https://www.gavi.org/sites/default/files/programmes-impact/our-impact/Evaluation-Gavi-COVID-19-Final-report.pdf

of "protect RI" contingency plans, increased intensive activities linked to sustaining demand and trust in vaccination and broader communication efforts.

The scope of eligible expenditures is broader under the reprogramming pathway (i. and ii.) than the Gavi mpox vaccination delivery pathway (only i.).

Ineligible expenditures for mpox vaccination delivery funding & CDS reprogramming for mpox outbreak response

- Outbreak response and vaccination related activities that are not aligned with countries' national or sub-national plans;
- Major infrastructure and capital investments;
- Significant expenditures that show no link to mpox;
- Trainings that are not grounded in WHO or relevant regional entities (such as Africa CDC) standards;
- Compensation to health workers that are not directly linked to mpox outbreak response, RI protection and that is not time-bound in nature;
- Procurement of non-performance, quality and safety (PQS) cold chain equipment;
- Deployment of data or digital health related efforts without establishing capacity to use data generated.

Process for applying to Gavi

Eligible countries should flag to their Gavi Senior Country Manager (SCM) and Programme Manager (PM) their interest in mpox outbreak funding support. The SCM/PM will provide guidance to the country on eligible activities that can be considered for funding support (as outlined in Delivery Funding section above) and the application process.

Sources of Funding for Mpox Vaccination Delivery based on Country's Vaccine Allocation Status

Country's Vaccine Allocation Status	Primary Source of funding for mpox vaccination delivery	Complementary Funding Source
Country with Gavi doses allocated (APA or Gavi-facilitated)	Mpox vaccination delivery funding	CDS Reprogramming
Country without Gavi doses allocated	CDS Reprogramming	N/A

Pathway 1: Mpox Vaccination Delivery Funding

For those countries that are eligible per the terms highlighted above, they are requested to develop their application using a simplified application form and a high-level budget.

Countries will have until 31 January 2025 to submit their application and required materials to proposals@gavi.org e-mail address, with their Gavi Senior Country manager (SCM) & Programme Manager (PM) in copy.

For applications received by 17:00 CET Wednesday⁷, Gavi will facilitate a rapid review with the Independent Review Committee (IRC), with the outcome of reviews expected by 17:00 CET Friday of the same week of receipt of the application.

Application document requirements for mpox vaccination delivery funding requests

- Completed mpox vaccination delivery funding application form https://www.gavi.org/news/document-library/mpox-vaccination-delivery-funding-application-form
- 2. A separate detailed Gavi budget file is not requested, but a high-level breakdown of the budget is requested as part of the application form.
- 3. Applications should include the signature of the Minister of Health (or delegated authority).
- 4. The application form should be accompanied by
 - i. the mpox vaccination plan and/or national Mpox Preparedness & Response Plan (draft or final version)
 - ii. Signed Gavi Terms and Conditions for mpox vaccines
 - iii. Evidence of accepting the allocation of Gavi facilitated doses

Pathway 2: CDS reprogramming

- Reprogramming of CDS grants based on a review of available funds, or activities that
 can be deprioritized, should be explored by eligible countries. Gavi does not advise
 countries to reprogram funds that are firmly committed towards other agreed priorities,
 such as Big Catch Up, priority COVID-19 and health system strengthening activities.
- CDS reprogramming requests can amount to \$5M or 20% of the grant value (whichever is the least) and will be reviewed by the Secretariat. Any requests

⁷ With the exception that applications will not be accepted or reviewed during the week of Wednesday 25th December 2024 and Wednesday 1st January 2025.

exceeding this threshold will be reviewed on an exceptional basis only. As per current reallocation operating procedures, the requests will be approved by the Country Team and segment Directors, without Independent Review Committee (IRC) review.

- Please follow the <u>reprogramming process steps</u> and complete the CDS reprogramming template (<u>EN & FR</u>).
- To facilitate identification of budget lines relevant to the mpox outbreak response, activities should be identified in the budget in each relevant line adding the text "mpox_XX" e.g.: "mpox_supervision transport", "mpox_freezer".

Document requirements for reprogramming requests:

- 1. Completed mpox outbreak response application form for reprogramming; [Application Form]
- 2. Budget reallocation budget template [CDS <u>English</u> & <u>French</u> / <u>HSS reprogramming template</u>]

This guidance note is relevant for the duration of Gavi's support for the mpox outbreak (linked to the duration of the outbreak declaration by WHO and Africa CDC) and may be subsequently updated as the outbreak and Gavi's response evolve.

FAQs

You can find frequently asked questions here



Annex 1 – Countries eligible for reprogramming of Gavi CDS grants

<u>List of African countries that have reported suspected or confirmed cases since beginning of 2024 (based on data from WHO mpox data dashboard, November 3rd 2024)⁸</u>

Burundi,
Cameroon,
CAR,
Congo Republio
Cote d'Ivoire
DRC
Ghana
Guinea
Liberia
Kenya
Nigeria
Rwanda
Uganda
Zambia

Zimbabwe

Note the Gavi Secretariat will continue to monitor reporting of suspected and confirmed cases across WHO and Africa CDC data – thus, this list of eligible countries may expand further.